Radiopharm Theranostics (NASDAQ:RADX) Shares Up 4.6% – Still a Buy?

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) shares rose 4.6% during trading on Thursday . The stock traded as high as $4.47 and last traded at $4.33. 24,689 shares were traded during trading, an increase of 18% from the average session volume of 20,944 shares. The stock had previously closed at $4.14.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Tuesday, April 21st. HC Wainwright assumed coverage on Radiopharm Theranostics in a report on Thursday, June 4th. They issued a “buy” rating and a $6.00 price objective for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $11.00.

Radiopharm Theranostics Trading Down 7.2%

The stock’s 50-day moving average is $4.46 and its two-hundred day moving average is $4.77.

Hedge Funds Weigh In On Radiopharm Theranostics

Several hedge funds and other institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. grew its holdings in shares of Radiopharm Theranostics by 100.0% in the third quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock worth $88,000 after acquiring an additional 8,000 shares during the period. Marex Group plc bought a new position in Radiopharm Theranostics in the fourth quarter valued at about $54,000. Jane Street Group LLC purchased a new position in Radiopharm Theranostics in the fourth quarter worth about $76,000. Virtu Financial LLC purchased a new position in Radiopharm Theranostics in the fourth quarter worth about $76,000. Finally, Hsbc Holdings PLC purchased a new position in Radiopharm Theranostics in the fourth quarter worth about $1,007,000.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.